Polygenic Score (PGS) ID: PGS003385

Predicted Trait
Reported Trait Ovarian serous carcinoma
Mapped Trait(s) ovarian serous carcinoma (EFO_1001516)
Released in PGS Catalog: Jan. 19, 2023
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name best_OV
Development Method
Name lassosum
Parameters s = 0.9, lambda = 0.01128838
Variants
Original Genome Build GRCh37
Number of Variants 144,810
Effect Weight Type beta
PGS Source
PGS Catalog Publication (PGP) ID PGP000413
Citation (link to publication) Namba S et al. Cancer Res (2022)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 100%
54,990 individuals (100%)
PGS Evaluation
European: 100%
1 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
GWAS Catalog: GCST004478
Europe PMC: 28346442
 54,990 individuals European NR

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM016260 PSS010083|
European Ancestry|
143,259 individuals
 PGP000413 |
Namba S et al. Cancer Res (2022)
 Reported Trait: ovarian serous carcinoma — AUROC: 0.717 R²: 0.0142 age, top 20 genetic principal components —

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS010083 C56, histology was one of the followings: Papillary serous cystadenocarcinoma; Serous cystadenocarcinoma; Serous cystadenoma, borderline malignancy; Serous papillary cystic tumor of borderline malignancy; Serous surface papillary carcinoma —
[
  • 367 cases
  • , 142,892 controls
]
 — European
(British)		 — UKB Controls were samples without any cancer diagnosis or self-reported cancer